1
|
Zhao Z, Li X, Wang Y, Liu C, Ling G, Zhang P. Biomimetic platelet-camouflaged drug-loaded polypyrrole for the precise targeted antithrombotic therapy. J Nanobiotechnology 2023; 21:439. [PMID: 37990207 PMCID: PMC10664675 DOI: 10.1186/s12951-023-02197-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2023] [Accepted: 11/06/2023] [Indexed: 11/23/2023] Open
Abstract
Lower extremity deep venous thrombosis (LEDVT) affects patient's quality of life for a long time, and even causes pulmonary embolism, which threatens human health. Current anticoagulant drugs in clinical treatment are hampered by the risk of bleeding due to poor targeting and low drug penetration. Here, we used platelet (PLT)-like biological targeting to enhance the delivery and accumulation of nanomedicines in thrombus and reduce the risk of bleeding. Meanwhile, the parallel strategy of "thrombus thermal ablation and anticoagulation" was applied to increase the permeability of drugs in thrombus and achieve the optimal antithrombotic effect. Polypyrrole (PPy) and rivaroxban (Riv, an anticoagulant drug) were co-assembled into platelet membrane-coated nanoparticles (NPs), PLT-PPy/Riv NPs, which actively targeted the thrombotic lesion at multiple targets in the platelet membrane and were thermally and drug-specific thrombolysed by 808 nm laser irradiation. The combination therapy resulted in up to 90% thrombolysis in a femoral vein thrombosis model compared to single phototherapy or drug therapy. The results showed that the nanoformulation provided a new direction for remote precise and controlled sustained thrombolysis, which was in line with the trend of nanomedicine towards clinical translation.
Collapse
Affiliation(s)
- Zhining Zhao
- Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, 110016, China
| | - Xiaodan Li
- Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, 110016, China
| | - Yan Wang
- Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, 110016, China
| | - Cheng Liu
- Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, 110016, China
| | - Guixia Ling
- Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, 110016, China.
| | - Peng Zhang
- Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, 110016, China.
| |
Collapse
|
2
|
Li S, Zhang K, Ma Z, Zhang W, Song Z, Wang W, Han H. Biomimetic Nanoplatelets to Target Delivery Hirudin for Site-Specific Photothermal/Photodynamic Thrombolysis and Preventing Venous Thrombus Formation. SMALL (WEINHEIM AN DER BERGSTRASSE, GERMANY) 2022; 18:e2203184. [PMID: 36344452 DOI: 10.1002/smll.202203184] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/23/2022] [Revised: 08/15/2022] [Indexed: 06/16/2023]
Abstract
Due to the high recurrence rate and mortality of venous thrombosis, there is an urgent need for research on antithrombotic strategies. Because of the short half-life, poor targeting capabilities, bleeding complications, and neurotoxic effects of conventional pharmacological thrombolysis methods, it is essential to develop an alternative strategy to noninvasive thrombolysis and decrease the recurrence rate of venous thrombosis. A platelet-mimetic porphyrin-based covalent organic framework-engineered melanin nanoplatform, to target delivery of hirudin to the vein thrombus site for noninvasive thrombolysis and effective anticoagulation, is first proposed. Owing to the thrombus-hosting properties of platelet membranes, the nanoplatform can target the thrombus site and then activate hyperthermia and reactive oxygen species for thrombolysis under near-infrared light irradiation. The photothermal therapy/photodynamic therapy combo can substantially improve the effectiveness (85.7%) of thrombolysis and prevent secondary embolism of larger fragments. Afterward, the highly loaded (97%) and slow-release hirudin (14 days) are effective in preventing the recurrence of blood clots without the danger of thrombocytopenia. The described biomimetic nanostructures offer a promising option for improving the efficacy of thrombolytic therapy and reducing the risk of bleeding complications in thrombus associated diseases.
Collapse
Affiliation(s)
- Shuting Li
- State Key Laboratory of Agricultural Microbiology, College of Life Science and Technology, Huazhong Agricultural University, Wuhan, Hubei, 430070, China
| | - Kai Zhang
- State Key Laboratory of Agricultural Microbiology, College of Life Science and Technology, Huazhong Agricultural University, Wuhan, Hubei, 430070, China
| | - Zhaoyu Ma
- State Key Laboratory of Agricultural Microbiology, College of Life Science and Technology, Huazhong Agricultural University, Wuhan, Hubei, 430070, China
| | - Weiyun Zhang
- State Key Laboratory of Agricultural Microbiology, College of Life Science and Technology, Huazhong Agricultural University, Wuhan, Hubei, 430070, China
| | - Zhiyong Song
- State Key Laboratory of Agriculture Microbiology, College of Science, Huazhong Agricultural University Wuhan, Wuhan, Hubei, 430070, China
| | - Wenjing Wang
- State Key Laboratory of Agriculture Microbiology, College of Science, Huazhong Agricultural University Wuhan, Wuhan, Hubei, 430070, China
| | - Heyou Han
- State Key Laboratory of Agricultural Microbiology, College of Life Science and Technology, Huazhong Agricultural University, Wuhan, Hubei, 430070, China
- State Key Laboratory of Agriculture Microbiology, College of Science, Huazhong Agricultural University Wuhan, Wuhan, Hubei, 430070, China
| |
Collapse
|
3
|
Chen L, Yang J, Fu X, Huang W, Yu X, Leng F, Yu C, Yang Z. A targeting mesoporous dopamine nanodrug platform with NIR responsiveness for atherosclerosis improvement. BIOMATERIALS ADVANCES 2022; 136:212775. [PMID: 35929293 DOI: 10.1016/j.bioadv.2022.212775] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/15/2021] [Revised: 03/07/2022] [Accepted: 03/21/2022] [Indexed: 05/27/2023]
Abstract
Atherosclerosis (AS), the formation of plaque lesions in the walls of arteries, causes many mortalities and morbidities worldwide. Currently, achieving site-specific delivery and controlled release at plaques is difficult. Herein, we implemented the strategy of constructing a bionic multifunctional nanoplatform (BM-NP) for targeting and improving plaques. BM-NPs were prepared based on probucol-loaded mesoporous polydopamine (MPDA) carriers and were coated with platelet membranes to impart bionic properties. In vitro experiments confirmed that BM-NPs, which respond to near-infrared (NIR) for drug release, remove reactive oxygen species (ROS), thereby reducing the level of oxidized low-density lipoprotein (ox-LDL) and ultimately helping to inhibit macrophage foaming. In vivo experiments proved that BM-NPs actively accumulated in plaques in the mouse right carotid artery (RCA) ligation model. During treatment, BM-NPs with NIR laser irradiation more effectively reduced the area of plaque deposition and slowed the thickening of the arterial wall intima. More importantly, BM-NPs showed the advantage of inhibiting the increase in triglyceride (TG) content in the body, and good biocompatibility. Hence, our research results indicate that intelligent BM-NPs can be used as a potential nanotherapy to precisely and synergistically improve AS.
Collapse
Affiliation(s)
- Lu Chen
- College of Pharmacy, Chongqing Key Laboratory for Pharmaceutical Metabolism Research, Chongqing pharmacodynamic evaluation engineering technology research center, Chongqing 400016, China
| | - Jiaxin Yang
- College of Pharmacy, Chongqing Key Laboratory for Pharmaceutical Metabolism Research, Chongqing pharmacodynamic evaluation engineering technology research center, Chongqing 400016, China
| | - Xiaoxue Fu
- College of Pharmacy, Chongqing Key Laboratory for Pharmaceutical Metabolism Research, Chongqing pharmacodynamic evaluation engineering technology research center, Chongqing 400016, China
| | - Wenyan Huang
- College of Pharmacy, Chongqing Key Laboratory for Pharmaceutical Metabolism Research, Chongqing pharmacodynamic evaluation engineering technology research center, Chongqing 400016, China
| | - Xiaojuan Yu
- College of Pharmacy, Chongqing Key Laboratory for Pharmaceutical Metabolism Research, Chongqing pharmacodynamic evaluation engineering technology research center, Chongqing 400016, China
| | - Feng Leng
- College of Pharmacy, Chongqing Key Laboratory for Pharmaceutical Metabolism Research, Chongqing pharmacodynamic evaluation engineering technology research center, Chongqing 400016, China
| | - Chao Yu
- College of Pharmacy, Chongqing Key Laboratory for Pharmaceutical Metabolism Research, Chongqing pharmacodynamic evaluation engineering technology research center, Chongqing 400016, China.
| | - Zhangyou Yang
- College of Pharmacy, Chongqing Key Laboratory for Pharmaceutical Metabolism Research, Chongqing pharmacodynamic evaluation engineering technology research center, Chongqing 400016, China.
| |
Collapse
|